Horizon Therapeutics (HZNP) Shares Sink 15% on Conference Commentary, JPMorgan Provides Context, Sees Buying Opportunity
Tweet Send to a Friend
JPMorgan analyst Chris Schott reiterated an Overweight rating and $140.00 price target on Horizon Therapeutics (NASDAQ: HZNP) but cut EPS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
